Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,646 shares of the company’s stock after selling 711 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Neurocrine Biosciences were worth $651,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the business. RFP Financial Group LLC grew its stake in Neurocrine Biosciences by 346.5% during the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after purchasing an additional 149 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in Neurocrine Biosciences in the second quarter valued at approximately $28,000. Innealta Capital LLC purchased a new position in Neurocrine Biosciences during the 2nd quarter worth approximately $30,000. New Covenant Trust Company N.A. acquired a new stake in Neurocrine Biosciences during the 1st quarter valued at approximately $32,000. Finally, EdgeRock Capital LLC purchased a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at $35,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Piper Sandler raised Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $131.00 to $159.00 in a report on Thursday, August 29th. Raymond James reissued an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Thursday, October 10th. JPMorgan Chase & Co. upped their price objective on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Citigroup raised their target price on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Finally, Oppenheimer upped their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $163.91.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Gary A. Lyons sold 11,570 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.43, for a total value of $1,740,475.10. Following the completion of the transaction, the director now directly owns 119,047 shares of the company’s stock, valued at $17,908,240.21. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Gary A. Lyons sold 11,570 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $150.43, for a total value of $1,740,475.10. Following the sale, the director now directly owns 119,047 shares in the company, valued at approximately $17,908,240.21. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William H. Rastetter sold 14,250 shares of the business’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the transaction, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.79. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,063 shares of company stock valued at $7,023,330 over the last quarter. 4.30% of the stock is owned by company insiders.

Neurocrine Biosciences Trading Down 1.1 %

NASDAQ NBIX opened at $123.98 on Friday. The stock has a fifty day simple moving average of $118.45 and a 200-day simple moving average of $133.21. The stock has a market cap of $12.55 billion, a PE ratio of 33.24 and a beta of 0.35. Neurocrine Biosciences, Inc. has a twelve month low of $103.63 and a twelve month high of $157.98.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.